The impact of guideline adherence on clinical outcomes in the management of chronic heart failure (CHF) has never been evaluated in Japan.
that, despite proven benefits for clinically important measures, including mortality and morbidity, a substantial proportion of patients who should be treated with an angiotensin-converting enzyme inhibitor (ACEI) do not receive these drugs. 1, 2) As in other fields of care, clinical practice guidelines in CHF management which translate medical research and expert opinion into recommendations for everyday practice have been introduced worldwide. [3] [4] [5] [6] Given that active intervention is more successful in changing processes than the passive dissemination of guidelines, 7) any attempt to procure the widespread implementation of a guideline by practicing physicians should be preceded by evaluation of the present conditions of adherence to it and the impact of its implementation on CHF outcomes.
For the first time in Japan, the results of valid clinical trials conducted through 1999 and expert summation thereof were integrated into the 'Guidelines for Treatment of Chronic Heart Failure', published by the Japanese Circulation Society (JSC) in November 2000. 8) Although the guideline appears to be disseminating gradually among not only specialist but also primary care physicians, little information has appeared concerning actual prescription rates of the recommended drug regimens. 9, 10) Further, the impact of guideline adherence on clinical outcomes in Japan has not been evaluated. Here, we investigated the impact of implementation or nonimplementation of JSC treatment guidelines for CHF on disease outcome, as measured by cardiovascular death and HF hospitalization in a single center.
METHODS

Study population:
Consecutive CHF patients admitted to Kitasato University Hospital for exacerbation of HF with left ventricular systolic dysfunction (LVSD) defined as an LV ejection fraction (LVEF) ≤ 40% at discharge from January 2004 until July 2006 were recruited. Patients with acute coronary syndrome or acute myocarditis as the underlying condition were excluded. Informed consent was obtained from all study subjects. Among 188 patients, 96 were excluded due to lack of compliance with outpatient management for HF, transfer to another institution, or inability to provide written informed consent, for example due to dementia or low ADL, giving a final study population of 92 patients. Endpoints defined as readmission for HF exacerbation or cardiovascular death (termed 'cardiac events') after hospital discharge until July 2007 were retrospectively analyzed. HF exacerbation was determined by two or more experienced cardiologists according to the Framingham criteria, together with other clinical data, including chest X-rays and echocardiography. The study procedure was in compliance with the institutional guidelines of Kitasato University and the principles outlined in the Helsinki Declaration. The institutional ethical review board on human research approved the study protocol. Indicators of adherence of medication to guidelines: Assessment was based on adherence to the 2000 JCS guideline for CHF management rather than the updated 2005 version, 6) because the former was still the main guidance used at the time covered by the study for class I drugs for pump failure, namely ACEI, betablockers (BB), spironolactone, diuretics (loop diuretics and thiazides), and cardiac glycosides, at hospital discharge, which was regarded as the start-point of chronic phase HF management.
Prescription of medications was determined individually and independently by senior cardiologists. Algorithms used to determine 'adherent' or 'nonadherent' status related solely to physician adherence to JCS guidelines, and not to patient compliance (Table I) . Symptomatic congestion mandating diuretic use was defined as the existence of one of jugular vein dilatation, pulmonary rales, hepatomegaly, pretibial edema, or radiographic pulmonary congestion. Based on the degree of benefit from more generalized evidence, and in a greater number of subjects, these 5 therapeutic agents were then further classified into two categories, namely ACEI plus BB as first-line therapy for LVSD and the other 3. Clinical evaluation and measurements: Biochemical laboratory data, New York Heart Association functional class (NYHA class), and echocardiography were evaluated on admission, at discharge, and 1 year after discharge. All clinical findings at discharge were sampled from the most recent data to discharge when HF was adequately controlled. Plasma B-type natriuretic peptide (BNP) was determined by sensitive noncompetitive immunoradiometric assay (Shionoria BNP ® , Shionogi, Japan) using venous blood samples taken after 15 minutes of rest. Echocardiography was performed transthoracically using a ProSound SSD-5000 (Aloka, USA). M-mode images were obtained in the left parasternal long-axis views for measurement of chamber dimensions, and LVEF was calculated by the 
RESULTS
Patient characteristics and events during follow-up: Patient characteristics are listed in Table II . Mean age at discharge was 62 ± 15 years, and 78% were male. The most frequent underlying disorders were ischemic heart disease (39%) and dilated cardiomyopathy (33%). Morphological examination by echocardiography showed LVEF of 30 ± 6% and LVDd of 59 ± 17 mm at discharge. Most of the subject patients were admitted at NYHA class III or IV and discharged at NYHA class I or II. Plasma BNP levels were decreased from 1183 ± 852 to 283 ± 354 pg/ mL during hospitalization. Seven patients died during follow-up (16.9 ± 10.9 months): 5 cardiovascular deaths (2 due to HF exacerbation and 3 sudden cardiac death) and 2 extra-cardiac deaths due to pneumonia or malignancy. Readmission for HF exacerbation, on the other hand, was observed in 22 cases (23.9%). Prescribed medication and guideline adherence for class I drugs (Table III) : With regard to drugs prescribed for HF, an ACEI was prescribed in 59 cases (64.1%) and angiotensin-II receptor blockers (ARB), positioned as class II drugs but now used equivalently in real-world clinical practice, in 39 cases (42.4%). The prescription rate for either or both ACEI and ARB was high (98.9%). Although ARB are recommended in the guidelines as alternatives for patients intolerant to ACEI due to, for example, the induction of dry cough, 30 patients received ARB despite the lack of any prior attempt to administer ACEI. In contrast to the high adherence to ACEI or ARB administration, prescription of another first-line drug, BB, was relatively low, at only 55 cases (59.8%). With regard to combined prescription of these first-line drugs, the combination of either ACEI or ACEI/ARB together with BB was administered in 35/92 (38.0%) or 54/92 (58.7%) of patients, respectively. Among the 27 patients receiving spironolactone as an aldosterone receptor blocker, administration was not indicated in 3 patients whose heart failure status was classified as mild, at NYHA II. Further, among subjects meeting the indication, namely a NYHA III-IV status, spironolactone was prescribed in only 28.2% (24/85). Digoxin, a cardiac glycoside, was admin- (24) 3 (3) 11 (12) 11 (12) 21 (23) 38 (41) 29 (32) Basal heart disease: I indicates ischemic heart disease; D, dilated cardiomyopathy; V, valvular heart disease; H, hypertensive heart disease and M, miscellaneous. Basic cardiac rhythm: SR indicates sinus rhythm; Af, atrial fibrillation; NYHA class, New York Heart Association functional class; sBP, systolic blood pressure; HR, heart rate; BNP, B-type natriuretic peptide; Cr, serum creatinine concentration; LVEF, left ventricular ejection fraction; and LVDd, left ventricular end-diastolic dimension. BMI indicates body mass index; Cr, serum creatinine concentration; af, atrial fibrillation; I, ischemic heart disease; D, dilated cardiomyopathy: V, valvular heart disease; H, hypertensive heart disease; M, miscellaneous; NYHA, New York Heart Association; sBP, systolic blood pressure; Ave HR, averaged heart rate; BNP, B-type natriuretic peptide; ACEI, ACE inhibitor; BB, beta-blocker; ARB, anigiotensin II receptor blocker plus other 1/ 2: together with 1 or 2 of the 3 HF drugs consisting of spironolactone, diuretics, or digitalis; LVEF, left ventricular ejection fraction; and LVDd, left ventricular end-diastolic dimension.
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Figure. Subsequent cardiac-event-free survival rate after discharge stratified by adherence to the prescription of class I drugs for pump failure.
The Kaplan-Meier curve demonstrated that patients prescribed at least both ACEI and BB (High GA ab) had significantly fewer cardiac events than those without either ACEI or BB (Low GA ab) ( Figure 1A) . Patients prescribed at least ACEI and BB together with one (High GA ab+1 versus Low GA ab+1; Figure 1B ) or two (High GA ab+2 versus Low GA ab+2; Figure 1C ) of the 3 other HF drugs, namely spironolactone, diuretics and a cardiac glycoside, also had significantly fewer cardiac events than their respective counterparts.
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istered in 43 cases; 13 with atrial fibrillation and 30 with sinus rhythm. Among patients with the class I indication of atrial fibrillation with increased heart rate, a cardiac glycoside was prescribed in 68% (13/19) . Diuretics excluding spironolactone were prescribed in 89 cases (96.7%), all of whom were given furosemide and 2 combined furosemide and thiazide. All patients in this study had experienced volume retention or symptomatic congestion requiring relief as a recommended condition for these drugs.
Guideline adherence as a predictor of cardiac events and improvement in clinical parameters: Among clinical parameters and the prescription of class I drugs for pump at discharge, univariate analysis showed that significant predictors of subsequent cardiac events were NYHA class and the use of ACEI plus BB, with or without the other 3 HF drugs (Table IV) . Among these parameters, multivariate analysis also revealed that the use of these HF drugs was an independent predictor of subsequent cardiac events irrespective of NYHA class (data not shown).
With regard to the prognostic significance of adherence to drug use according to these CHF guidelines from the JCS, we also evaluated the relationship between cardiac events after hospital discharge and guideline adherence to the ACEI indicates ACE inhibitor; BB, beta-blocker; BMI, body mass index; af, atrial fibrillation; NYHA, New York Heart Association; Ave HR, averaged heart rate; sBP, systolic blood pressure; I, ischemic heart disease; D, dilated cardiomyopathy; V, valvular heart disease; H, hypertensive heart disease; M, miscellaneous; Ave HR, average heart rate; BNP, B-type natriuretic peptide; Cr, serum creatinine concentration; LVEF, left ventricular ejection fraction; and LVDd, left ventricular end-diastolic dimension. Figure 1A demonstrates that patients prescribed at least both ACEI and BB (High GA ab, n = 35) had significantly fewer cardiac events than those without either ACEI or BB (Low GA ab, n = 57) (P = 0.0036), despite the absence of significant differences in clinical characteristics at discharge as the start-point of the follow-up (Table V) . For ARB also, significantly fewer cardiac events were recorded in patients receiving both ACEI and/or ARB plus BB (n = 54) than in the other patients (n = 38) (P = 0.0067). Further, concerning the contribution to surrogate indicators for HF status, NYHA class and plasma BNP, but not LVEF and LVDd, were significantly improved during the 1 year after discharge in the High GA ab compared to the Low GA ab group (Table VI) .
Although our findings did not reveal whether individual prescription of the 3 other HF drugs, spironolactone, diuretics, or digitalis, was a significant predictor of improved prognosis (data not shown), patients prescribed at least ACEI and BB together with one or two of these 3 HF drugs also had significantly fewer cardiac events than their respective counterparts (P = 0.0195 for High GA ab+1 versus Low GA ab+1, shown in Figure 1B ; P = 0.0166 for High GA ab+2 versus Low GA ab+2, shown in Figure 1C , respectively). Clinical background of patients not prescribed BB: Although low adherence to BB prescription was observed in this study, as stated above, we did not observe a clear contraindication to BB administration in most of these unprescribed patients. A likely background to this lack of prescription included 1) previous history of suspected bronchial asthma (n = 2), 2) patient statement of drug allergy to previous BB administration (n = 3), 3) asymptomatic hypotension with systolic BP of 88-95 mmHg (n = 6), 4) renal dysfunction with serum creatinine levels of 1.44-2.73 mg/dL n = 7), 5) prolonged PQ interval of 0.21-0.28 sec (n = 5), 6) bradycardia (n = 10), and 7) unknown (n = 4). Table VII shows the clinical characteristics of the 10 patients not receiving BB, presumably due to bradycardia. A decreased basal heart rate (HR) of 55/min or less was clearly observed, although digoxin was administered to half these patients, presumably due to decreasing ventricular response concomitant with atrial fibrillation.
DISCUSSION
Prescription trends in practice compared with HF guidelines: Previous epidemiological reports have suggested that utilization of recommended medications for CHF derived from LVSD is suboptimal; or in other words, that CHF guidelines for pharmacological therapy are not closely adhered to. The EuroHeart Failure Survey reported in 2003 that the recommended first-line combination of ACEI and BB based on diuretics was prescribed to only 17% of patients at discharge for HF exacerbation, 11) a population equivalent to that of our study. In the United States also, concomitant use of ACEI/ARB and BB remained at a low 16% in 2000, albeit with a gradual increase over time by a mean 1.2% annually. 12) To date, very little information on the clinical characteristics and prognosis of patients with CHF has been available in Japan, although a registry from affiliated hospitals in Fukuoka 13) and the Tohoku district 8) in the same period demonstrated a combined receipt of ACEI/ARB and BB in 22% and 20% of cases, respectively. Further, the efficacy of the guidelines described above must depend in part on the experience of the practitioners implementing them, such as HF specialist/hospital cardiologists vs. primary care/general physicians. Tsutsui, et al recently reported Residual myocardial ischemia negative (-) indicates no residual ischemia as demonstrated in myocardial scintigraphy; SR, sinus rhythm; Af, atrial fibrillation; Cr, serum creatinine concentration; NYHA, New York Heart Association classification; sBP, systolic blood pressure; HR, averaged heart rate; DCM, dilated cardiomyopathy; and IHD, ischemic heart disease. the first diverse, large-scale, prospective multicenter database in Japan, named JCARE-GENERAL. 9) Their analysis showed that ACEI/ARB and BB were more often prescribed to outpatients with HF who were managed by hospital cardiologists than by primary care physicians, at the rate of 68.7% versus 50.6%, and 38.3% versus 17.5%, respectively.
Here, we have demonstrated the absence of any extreme underutilization of first-line HF drugs, albeit in a restricted-setting survey at a single center consisting of hospital cardiologists: ACEI/ARB was administered to almost all HF patients with LVSD, and the prescription rate of BB or the combination of ACEI/ ARB and BB was more than twice that reported in the studies above. These differences are possibly due to the fact that our patients were managed mostly by individual practitioners but also partly under an organized system established by senior HF specialists. The most common barriers to guideline implementation include not only individual disability, such as a lack of awareness/agreement and inertia in practice, but also systematic disorganization, including external barriers and a lack of staff support. 7) These findings suggest that the promotion of guidelines requires the involvement of facilitators to motivate and encourage usage among practitioners. Adherence to CHF guidelines related to improved prognosis: Numerous studies have shown that adherence to clinical practice guidelines has the benefits of reducing both disease morbidity and mortality as well as overall treatment costs in chronic medical conditions such as diabetes, hypertension, coronary artery diseases, and osteoporosis. 14) Although it was estimated in a previous analysis that up to one-third of HF admissions might be preventable through appropriate use of evidence-based medications and guideline observance, 15) to date only one report demonstrating a direct impact of adherence to guidelines on outcome using a global prescribing score in a CHF population has appeared. Using the MAHLER survey, Komajda, et al investigated the consequences of adherence to pharmacological care guidelines in 1410 CHF patients by 150 randomly selected cardiologists from 6 European countries on the rate of cardiac events over a 6-month period. 16) Using guideline adherence indicators for ACEI, BB, spironolactone, diuretics, and cardiac glycosides, they demonstrated a significant increase in cardiac-event-free rates in accordance with increasing tertiles of mean adherence score value.
To the best of our knowledge, the present study is the first report in Japan to investigate the clinical benefit of pharmacological intervention in a CHF population with LVSD from the aspect of adherence to the national guideline. We analyzed the prognostic benefit of the prescription of 5 class I drugs for pump failure, as described above; among these processes, these 5 therapeutic agents were classified into two categories, namely ACEI and BB as first-line therapy and the latter 3, based on the stronger benefit of the former from more generalized evidence in a larger patient population. Our results demonstrate that CHF patients with high prescription rates for the first-line agents ACEI and BB obtained significantly and independently better prognostic outcomes, together with subsequent improvements in clinical surrogate markers for HF status, such as NYHA status and BNP level. These results confirmed the clinical benefits of not only the evidence-based pharmacological intervention itself but also practitioner attitudes of adherence to guidelines concerning the prescription of ACEI and BB. For the 3 other HF drugs, on the other hand, although their individual prescription did not improve prognostic outcomes, their addition to the first-line drugs did not affect the superiority of ACE plus BB in improving long-term prognosis. Diuretics and cardiac glycosides should thus be considered as class I drugs on the basis that, unlike ACE and BB, they are recommended for symptomatic improvement only, and not for any beneficial effect on long-term prognosis. It is unclear why the prescription of spironolactone, an evidence-based HF drug used to prolong life in severe CHF only, did not show a prognostic benefit, but may be at least partly due to an insufficient number of patients to allow analysis of the relationship between prescription rate and clinical impact. Clinical implications and future prospects: While this study clearly demonstrates the efficacy of adherence to guidelines on clinical outcome, an immediate question must be how these guidelines can be spread and incorporated into actual practice. For this purpose, it may be useful to first investigate physician reluctance to adhere to the guideline. Although we particularly identified the superiority of ACE plus BB in improving prognosis, BB was prescribed in only about half of the patients, in contrast to the high adherence to ACEI or ARB use.
Why doctors were reluctant to prescribe BB is not entirely clear, but the contraindications and cautions required for its use have lead to considerable concern about whether it can be safely used in ordinary clinical practice. Although we did not identify a clear contraindicative background in most patients not receiving it, the presence of bradycardia might be a candidate. Most clinical trials and guidelines adopt a clear strategy of targeting individual dosing levels such that HR is maintained at < 60/min; 17) nevertheless, it remains unclear how to precisely judge contraindications for lower HR limits, and further how to deal with borderline clinical situations. Notably, digoxin was administered to half of the patients not receiving BB due to bradycardia concomitant with atrial fibrillation. We speculate that digitalis was first administered during acute HF management to control HR in these patients. Given evidence for the superior prognostic benefit of BB compared to cardiac glycosides, however, initial treatment with digoxin should not preclude the subsequent introduction of BB. 18, 19) Digoxin can be withdrawn if excessive bradycardia develops once the exacerbated HF is relieved during com- A clear method for improving guideline adherence in HF has yet to be determined. From the viewpoint of practitioners, most recognize guideline-based suggestions as useful educational tools but feel these are "too rigid", "hamper autonomy", and are "oversimplified". 20) We speculate that the imperfect transfer from evidence to everyday practice owes to a fear of side effects or adverse events in guideline-oriented therapy. Practical, easy-to-follow advice on dosing is required, including initiation and maintenance as well as the identification of potential problems; along with clear recommendations on how to handle these should they arise, especially for nonspecialists. These practical recommendations should be provided as a supplement rather than replacement to existing HF guidelines. 21) It has also been suggested that active guideline interventions, through their use of a system-oriented approach, are more successful than the passive dissemination of guidelines. 7) Previous studies have demonstrated the effectiveness of such implementation systems for nurse facilitators, 22) collaborative multidisciplinary hospital teams, 23) and quality-of-care report cards. 24) The interventions are particularly effective when undertaken in conjunction with the national support or collaboration of scientific societies in promoting their spread through interactive workshops to engage and educate multidisciplinary hospital staffs and teams, such as the American Heart Association's 'Get With The Guidelines' program. 25) It must be recognized, therefore, that the efficacy of guidelines depends in part on the type of practitioners who implement them (specialist versus primary care), the type of hospital in which the guidelines are used, the complexity of the guidelines ("user-friendliness"), and the availability of the guidelines to practitioners. 26) Study limitation: Several limitations of this study warrant mention. First, the study was a retrospective study conducted in a single hospital and the sample number was low. Second, the paucity of concrete suggestions for absolute and relative contraindication in the JCS guidelines made it difficult to evaluate the impact of comorbidities on prescription behavior. For this reason, we regarded 'the recommended condition for class I' in Table III as a straight indication without qualification by any potential contraindication. Third, because the JCS guidelines do not provide precise dosage guidance for most of the subject drugs, we were unable to estimate adherence to the prescribed dose of HF drugs. Moreover, actual dosages were not congruent with product information provided under the national public insurance system as based on large randomized trials, mostly conducted in countries other than Japan. This difference explains our use of a binomial analysis of classical adherence to prescription, ie, 'yes' or 'no'.
